Trial Profile

A Study of Complete Molecular Response for Chronic Myeloid Leukemia in Chronic Phase Patients, Treated With Dasatinib.

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 07 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Dasatinib (Primary)
Indications Chronic myeloid leukaemia
Focus Therapeutic Use
Acronyms CMR-CML

Most Recent Events

14 Jun 2015 Results presented at the 20th Congress of the European Haematology Association.
14 Jun 2015 Status changed from active, no longer recruiting to completed, according to abstract presented at 20th Congress of the European Haematology Association, which stated that patients were enrolled between 6 aug 2011 and 17 Jan 2013.
29 Apr 2011 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com